Recurrent Malignant Testicular Germ Cell Tumor Terminated Phase 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0028803 (Recurrent Malignant Testicular Germ Cell Tumor)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00042952Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian CancerTreatment